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Murine cytomegalovirus (MCMV) Smith strain is widely used in mouse models to study HCMV infections. Due to
high serial passages, MCMV Smith has acquired genetic and biological changes. Therefore, a low passaged strain
would be more relevant to develop mouse models. Here, the pathogenesis of an infection with MCMV Smith was
compared with that of an infection with a low passaged Belgian MCMV isolate HaNa1 in BALB/c adult mice
following oronasal inoculation with either a low (104 TCID50/mouse) or high (10
6 TCID50/mouse) inoculation dose.
Both strains were mainly replicating in nasal mucosa and submandibular glands for one to two months. In nasal
mucosa, MCMV was detected earlier and longer (1–49 days post inoculation (dpi)) and reached higher titers with
the high inoculation dose compared to the low inoculation dose (14–35 dpi). In submandibular glands, a similar
finding was observed (high dose: 7–49 dpi; low dose: 14–42 dpi). In lungs, both strains showed a restricted
replication. In spleen, liver and kidneys, only the Smith strain established a productive infection. The infected cells
were identified as olfactory neurons and sustentacular cells in olfactory epithelium, macrophages and dendritic
cells in NALT, acinar cells in submandibular glands, and macrophages and epithelial cells in lungs for both strains.
Antibody analysis demonstrated for both strains that IgG2a was the main detectable antibody subclass. Overall, our
results show that significant phenotypic differences exist between the two strains. MCMV HaNa1 has been shown
to be interesting for use in mouse models in order to get better insights for HCMV infections in immunocompetent
humans.Introduction
Human cytomegalovirus (HCMV), also known as human
herpesvirus 5 (HHV-5), is the prototype member of the
Betaherpesvirinae within the family of the Herpesviridae.
It is an ubiquitous virus with a worldwide distribution [1].
It is the main cause of congenital infections in the world,
affecting 0.5–2.0% of live births [2,3] and leading to cen-
tral nervous damage, congenital deafness and mental re-
tardation [4-7]. HCMV infection is also harmful for the
immunocompromised individuals, such as HIV patients* Correspondence: Shunchuan.Zhang@Ugent.be; hans.nauwynck@UGent.be
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asymptomatic in the immunocompetent host [8].
Due to the strict species-specificity of HCMV, it is not
possible to study this virus in experimental animals.
Therefore, it is necessary to set up animal models for
the study of HCMV. Up till now, a number of CMV in-
fections in various animal species have been utilized for
modeling HCMV infection. Among the animal CMVs,
pathogenesis has been reported for rhesus macaque
CMV, porcine CMV, guinea pig CMV, rat CMV and
murine CMV [9-13]. The mouse model with MCMV is
the most commonly and widely used animal model for
HCMV study, due to the following reasons: (1) MCMV
shares many features with HCMV [4], (2) the genomes
of mice and MCMV are fully sequenced [14,15] and (3)is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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reproductive rate make them most suitable.
MCMV has been studied for more than 60 years. Most
published studies used the MCMV Smith strain or
MCMV K181 derived from the Smith strain, which were
highly passaged in vitro or in vivo. It is now apparent
that strains or variants of MCMV Smith that are in
common use have acquired genetic and biological differ-
ences during passaging [16,17]. The same problem has
been discussed for HCMV, where serially passaged la-
boratory strains, such as the commonly used HCMV
AD169, exhibit significant biological differences com-
pared to the clinical isolates of HCMV [18,19]. There-
fore, using serially passaged strains of MCMV may not
be able to reproduce the full range or extent of virus
replication and clinical outcome that are associated with
HCMV infections. It is important that more emphasis is
being placed on the use of recent isolates of MCMV and
avoiding cell culture passaging of these isolates.
Besides the passage history, the inoculation route is an
important factor during in vivo studies as well. The
inoculation route should mimic the natural route of
MCMV infection. Most of the published studies on
MCMV have utilized the intraperitoneal inoculation,
sometimes intracerebral, orbital or intravenous inocula-
tion, none of which can be considered as being natural
[20]. Although intramuscular or subcutaneous inocula-
tion mimics natural infection upon biting, only intrana-
sal and oral inoculations are widely accepted as the
route of natural infection. Unfortunately, there is very
limited information on natural infection upon oronasal
inoculation, with only a few studies on viral kinetics,
organ and tissue tropism, and host response [21-23].
In the present study, we have used two MCMV strains
(low passaged MCMV HaNa1 isolate and highly pas-
saged MCMV Smith strain) to set up mouse models
using the natural route of infection (oronasally) with a
low (104TCID50 per mouse) and high (10
6TCID50 per
mouse) inoculation dose without sedation/anesthesia in
order to compare the pathogenesis of a low passaged
isolate HaNa1 and the well-studied Smith strain.
Materials and methods
Ethics statement
All animal experiments (Case number 2013–47) were
approved by the local Ethical Committee of the Faculty
of Veterinary Medicine, Ghent University.
Cells and viruses
Primary BALB/c mouse whole fetus cells (MWFc) at
passage 2 were propagated at 37 °C and 5% CO2, in
minimum essential medium with 10% fetal calf serum
(FCS) and a mixture of antibiotics (100 U/mL penicillin,
100 μg/mL streptomycin and 50 μg/mL gentamicin).Viruses used in the present experiments were the second
passage of clone1 of the MCMV HaNa1 isolate, which
was isolated by our laboratory from a domestic mouse,
and the MCMV Smith strain at unknown passage. Up
till now, seven parts of the MCMV HaNa1 genome have
been sequenced and submitted to GenBank: m06 gene
(accession No.: KR184668), m033 gene (accession No.:
KR184669), mck-2 including exon1 (m131 gene) and
exon2 (m129 gene) (accession No.: KR184670), m138
gene (accession No.: KR184671), m144 gene (accession
No.: KR184672), m152 gene (accession No.: KR184673)
and m157 gene (submission ID: 1840944).
Multistep growth curves of two MCMV strains in MWFc
In order to have a better understanding of the in vitro
viral replication kinetics of both MCMV strains, a
growth curve analysis was performed. Monolayers of
MWFc in 24-well plates were inoculated in triplicate
with MCMV HaNa1 or MCMV Smith at 104 TCID50/
well. After inoculation for 1 h at 37 °C with 5% CO2, the
inoculum was removed, and cells were washed three
times with 2 mL PBS. Afterwards, 1 mL of fresh culture
medium was added per well. The supernatants (1 mL)
with the extracellular virus and the infected cells con-
taining intracellular virus, which were resuspended in
1 mL PBS, were collected at 1, 12, 24, 48 and 72 hpi.
The virus inactivation curve was determined by keeping
cell free virus in culture medium at 37 °C with 5% CO2.
Samples were taken at different time points. The sam-
ples were stored at −70 °C upon use at the end of the
experiment. All samples were thawed and cleared of cel-
lular debris, and then titrated to determine 50% tissue
culture infectious dose (TCID50) according to the Reed
and Muench formula [24].
Animals and virus inoculation
A total of 135 specific pathogen-free 8-week-old BALB/c
female mice were used. In both low dose groups (36
mice/group), each mouse was inoculated with 100 μL
PBS containing 104 TCID50 MCMV HaNa1 or MCMV
Smith via intranasal (25 μL) and peroral (75 μL) routes
without sedation/anesthesia. For the intranasal inocula-
tion, a small amount of inoculum (5 μL) was repeatedly
instilled in each nostril. Each application was done with
several minutes interval. For the oral inoculation, 25 μL
inoculum was given three times with a few minutes
interval between each inoculation. Mice were kept in
isolation and fed ad libitum. Three inoculated mice were
euthanized at each time point (1, 3, 5, 7, 10, 14, 17, 21,
28, 35, 42 and 49 days post inoculation (dpi)). In both
high dose groups (30 mice/group), each mouse was inoc-
ulated with 100 μL PBS containing 106 TCID50 MCMV
HaNa1 or MCMV Smith via intranasal (25 μL) and per-
oral (75 μL) routes using the same methodology. Three
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5, 7, 10, 14, 17, 21, 35 and 49 dpi). Another 3 mice were
mock inoculated with PBS and euthanized at the end of
the experiment.Collection of saliva, blood and tissues
Saliva was collected by swabs and stored in 0.3 mL of
cold sterile PBS containing 1% fetal calf serum and a
mixture of antibiotics (100 U/mL penicillin, 100 μg/mL
streptomycin and 50 μg/mL gentamicin). Upon
anesthesia with 130 μL of 10 mg/mL sodium pentobar-
bital (KELA, Belgium) per mouse, 0.5 mL blood was col-
lected from the orbital sinus with a heparinized pasteur
pipet and kept in an eppendorf with 0.5 mL PBS
containing 5 U/mL heparin (Leo Pharma, Zaventem,
Belgium). Then, plasma was harvested through centrifu-
gation (200 g for 10 min) and stored at −70 °C for virus
and antibody titration. Peripheral blood mononuclear
cells (PBMC) were isolated on a Ficoll-Paque cushion
according to manufacturer’s protocol (GE Healthcare),
washed three times, resuspended in 0.5 mL RPMI and
counted with a haemocytometer. The fresh PBMC were
used for co-culture studies. After blood collection,
mouse was euthanized with 200 μL of 10 mg/mL sodium
pentobarbital (KELA, Belgium). Various tissues were col-
lected under aseptic conditions from the nerve system
(olfactory bulb and brain), from the respiratory system
(nasal mucosa, nasopharynx-associated lymphoid tissues
(NALT), pharynx, trachea and lungs), from the alimen-
tary system (submandibular glands, esophagus and small
intestines), from the abdominal organs (liver and kid-
neys), from the reproductive system (uterus and ovaries)
and from the lymphoid organs (thymus and spleen).
One part of an organ was stored at −70 °C for virus ti-
tration. The other part was snap frozen with methocel
and stored at −70 °C for immunofluorescence staining.Virus titration of tissues
A five percent homogenate was made of all collected tis-
sues for virus titration. Briefly, tissues were thawed,
weighed and homogenized by using a pestle, a small vol-
ume of sterile sand and DPBS with 0.9 mM CaCl2, 0.5 mM
MgCl2 × 6H2O and 0.002% phenol red, supplemented with
2% FCS and a mixture of antibiotics (100 U/mL penicillin,
100 μg/mL streptomycin and 50 μg/mL gentamycin).
Afterwards, the supernatants were collected after cen-
trifugation (2400 g, 10 min). Virus titration was per-
formed on the second passage of MWFc. After 7 days,
the presence of a cytopathic effect (CPE) was assessed
by light microscopy (Olympus Optical Co., Hamburg,
Germany) and virus titer was calculated as 50% tissue
culture infectious dose (TCID50) according to the Reed
and Muench formula [24].Co-culture of PBMC
To examine the cell-associated viremia in PBMC, co-
culture assays were performed. MWFc (2 × 105/well)
were seeded in 24-well plates two days prior to co-
culture. Freshly isolated PBMC were brought on the
monolayer (PBMC from one mouse were equally divided
into 2 wells of a 24-well plate) and covered with 1 mL
carboxymethylcellulose (CMC) medium (1/4 2xMEM, 1/
4 2 × RPMI, 1/2 2 × CMC supplemented with 5% FCS,
100 U/mL penicillin, 100 μg/mL streptomycin, 50 μg/mL
gentamicin, 0.1 mM non-essential amino acids (NEAA)
and 1 mM Sodium pyruvate), and the plates were cen-
trifuged 750 g for 10 min, afterwards cultivated at 37 °C
in the incubator for 8 days. Plaques were counted with
a light microscopy (Olympus Optical Co., Hamburg,
Germany).
Production of biotinylated polyclonal anti-MCMV
antibodies (pα-MCMV Abs)
Anti-MCMV Smith hyperimmune sera were prepared as
described before by Woolf et al. with slight modification
[25]. Briefly, MCMV Smith was grown in MWFc, the
virus was released by sonication and virus suspension
was clarified to remove cellular debris by centrifugation
(4000 g for 20 min). Mice were inoculated with 106
TCID50 of clarified MCMV Smith intraperitoneally (IP),
followed by two further IP inoculations at 2-week inter-
vals. Afterwards, the plasma was collected at 7 days post
last injection. IgG was isolated from plasma using Pro-
tein G Sepharose™ 4 Fast Flow (GE Healthcare), and pro-
tein concentration was determined by NanoDrop 2000
(Thermo Fisher Scientific). The purified antibodies were
biotinylated with biotin reagents (EZ-Link® Sulfo-NHS-
LC-Biotin, Thermo Fisher Scientific).
pα-MCMV Abs were tested for their reactivity against
viral immediate early proteins, early proteins or late pro-
teins by a co-localization assay of pα-MCMV Abs and
murine monoclonal antibodies against immediate early
protein (mouse anti-m123/IE1, CROMA101, isotype
IgG1 (Capri, Croatia)), early protein (mouse anti-M112-
113/E1, isotype IgG1 (Capri, Croatia)) and late protein
(mouse anti-M55/gB, isotype IgG2b (Capri, Croatia)).
The co-localization assay showed that pα-MCMV Abs
recognized the viral early and late proteins but not viral
immediate early proteins.
Quantification of MCMV-infected cells in the nasal
mucosa, lungs and submandibular glands
Immunofluorescence was used to quantify MCMV-
infected cells in tissues (nasal mucosa, lungs and sub-
mandibular glands) that were MCMV HaNa1/MCMV
Smith-positive after virus titration. The number of
MCMV-infected cells in the nasal mucosa, submandibu-
lar glands and lungs of mice inoculated with the high
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culated. Forty consecutive cryosections (12 μm) per
organ were fixed in 4% paraformaldehyde at 4 °C for
10 min and permeabilized with 0.1% Triton X-100
(Sigma) at room temperature (RT) for 10 min. Tissue
sections were pretreated for 30 min with 10% negative
goat serum and followed by incubating with pα-MCMV
Abs (1:30) at 37 °C for 1 h. The cryosections were washed
three times with PBS and incubated with the secondary
antibodies: streptavidin Alexa-fluor® 488 conjugate, 1:200
(Invitrogen) at 37 °C for 1 h. After three washings, cell
nuclei were stained with 10 μg/mL Hoechst 33342 (Invi-
trogen) at RT for 10 min. Finally, cryosections were
mounted with glycerin-DABCO (Acros Organics).
Infected cells within each cryosection were quantified
with the Leica TCS SPE laser-scanning confocal micros-
copy (magnification 200×, Leica Microsystems, GmbH,
Wetzlar, Germany) according to the quantification
method of Beyer et al. [26]. Forty consecutive 12 μm-
sections were analyzed per organ. The total size of
the analyzed sections was the sum of the sizes of the
individual visual fields at a 200× magnification (diam-
eter 1 mm). Finally, the number of MCMV-infected
cells was calculated as a value per 10 mm2, independ-
ent of their localization and distribution within the
cryosection.
Identification of MCMV-infected cells in the nasal mucosa,
lungs and submandibular glands
Immunofluorescence double staining was performed to
identify MCMV-infected cells in the nasal mucosa, lungs
and submandibular glands. Twelve μm viral antigen-
positive cryosections of nasal mucosa, lungs and sub-
mandibular glands from 3, 7, 14 and 35 dpi were
prepared following the aforementioned protocol. Sec-
tions were incubated at 37 °C for 1 h with pα-MCMV
Abs (1:30) and cell markers (rabbit polyclonal anti-
cytokeratin-18 for epithelia, 1:150 (Abcam); goat anti-
olfactory marker protein for olfactory neurons [27],
1:500 (Wako); rat anti-mouse CD68/FITC-rat-anti-
mouse F4/80 for tissue macrophages, 1:50 (AbD Sero-
tec); hamster anti-mouse CD11c for dendritic cells, 1:50
(eBioscience); rat anti-mouse B220 for pan-B cells, 1:50
(Biolegend) and Alexa Fluor® 488-hamster-anti-mouse
CD3 for T cells). The cryosections were washed three
times with PBS and incubated at 37 °C for 1 h with the
corresponding secondary antibodies: streptavidin-Texas
Red-X or FITC conjugate, 1:200 (Invitrogen); FITC-goat-
anti-rabbit IgG, 1:200 (Invitrogen); Alexa Fluor® 594-
rabbit-anti-goat IgG, 1:200 (Invitrogen); Alexa Fluor®
488-goat-anti-rat IgG, 1:200 (Invitrogen); Alexa Fluor®
488-goat-anti-hamster IgG, 1:200 (Jackson ImmunoRe-
search) and Alexa Fluor® 488-goat-anti-rat IgG, 1:200
(Invitrogen). After washing three times, cell nuclei werecounterstained with 10 μg/mL Hoechst 33342 (Invitro-
gen) at RT for 10 min. Finally, cryosections were
mounted with glycerin-DABCO (Acros Organics) and
analyzed with the Leica TCS SPE laser-scanning con-
focal microscopy (Leica Microsystems, GmbH, Wetzlar,
Germany).
Determination of total and isotype-specific anti-MCMV
antibody titers
The titer of total and isotype specific anti-MCMV anti-
bodies were determined in immunoperoxidase monolayer
assays (IPMA) [28]. Briefly, monolayers of immortalized
mouse embryo fibroblasts (MEFs) [29] in 96-well plates
were inoculated with MCMV HaNa1 or MCMV Smith
(103 TCID50 per well), and cultivated for 3 days (37 °C,
5% CO2). Afterwards, the culture medium was re-
moved, and cells were washed with PBS and dried at
37 °C for 1 h. The plates were covered with plastic
covers and stored at −20 °C until use. Plates were
thawed at RT and cells were fixed with 4% paraformal-
dehyde for 10 min at RT. The paraformaldehyde was
removed, and cells were washed twice with PBS. After-
wards, the cells were treated with 100% methanol sup-
plemented with 1% H2O2 at RT for 5 min. Plates were
washed twice with PBS and serial twofold dilutions of
plasma were added and incubated at 37 °C for 1 h.
Plates were washed three times with PBS. To determine
the virus-specific immunoglobulin classes and sub-
classes, 50 μL biotinylated secondary antibody (rat anti-
mouse IgA biotin, 1:100, (eBioscience); rat anti-mouse
IgM biotin, 1:100, (eBioscience); sheep anti-mouse IgG
biotin, 1:100, (GE healthcare); rat anti-mouse IgG1 bio-
tin, 1:100, (eBioscience); rat anti-mouse IgG2a biotin,
1:100, (eBioscience); rat anti-mouse IgG2b biotin, 1:100,
(Biolegend); goat anti-mouse IgG2c biotin, 1:100,
(abcam); rat anti-mouse IgG3 biotin, 1:100, (Biolegend))
were added respectively and incubated at 37 °C for 1 h.
Afterwards, plates were washed three times and 50 μl
streptavidin-biotin horseradish peroxidase complex
(1:200) was added per well and incubated at 37 °C for
1 h. Plates were washed three times and 50 μL of a sub-
strate solution of 3-amino-9-ethylcarbazole (1/20) in
0.05 M acetate buffer, pH 5, with 0.024% H2O2 was
added to each well and kept in RT for 30 min. Finally,
the reaction was stopped with sodium acetate and the
IPMA titer was calculated as the reciprocal value of the
highest serum dilution that induced visual staining of
infected MEFs as determined by a light microscopy
(Olympus Optical Co., Hamburg, Germany). All afore-
mentioned biotinylated secondary antibodies have been
validated with sera from mice inoculated with influenza
A/New Caledonia/20/99 (NC) virus by IPMA. In
addition, the specificity of biotinylated secondary IgG
antibodies had also been assessed with a panel of
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antibodies with known subclasses (mouse anti-m112-
113, CROMA 103, IgG1; mouse anti-M123, IE1.01,
IgG2a; mouse anti-m55-MCMV, CROMA7, IgG2b;
mouse anti-m04-MCMV, m04-KAC.10, IgG2c; all were
purchased from Capri, Croatia). No apparent cross re-
action was found (data not shown).
Complement-dependent neutralization test
Hyperimmune sera to CMVs were found to mainly con-
tain complement-requiring neutralizing antibodies. Assays
to measure neutralizing antibody titers were performed as
described before by Farrell and Shellam and Lawson et al.
with a few modifications [30,31]. At day one, serial twofold
dilutions of heat-inactivated (56 °C, 30 min) plasma in
MEM (from 1:2 to 1:512) were incubated with an equal
volume containing 500 TCID50 MCMV Smith or 700
TCID50 MCMV HaNa1 for 23 h at 37 °C. Meanwhile,
MWFc were trypsinized and seeded in 96-well plates with
100 μL per well at a concentration of 2.5 × 105 cells/mL.
After 23 h, 25 μL of guinea pig complement (0.5 μg/μL)
was added to the virus/serum dilution mixtures for incu-
bating another 1 h at 37 °C in a 5% CO2 incubator. Then,
the medium of cells was removed and the mixtures of
serum/virus/complement were added to the confluent cell
monolayers. The plates were kept for 7 days at 37 °C. The
neutralizing antibody titer was expressed as the reciprocal
of the highest dilution that was able to completely block
MCMV infection in MWFc.
Results
Growth kinetics of MCMV strains in MWFc
In the first experiment, the in vitro viral growth charac-
teristics of MCMV HaNa1 and MCMV Smith were
compared in MWFc, as shown in Figure 1. The study
demonstrated that HaNa1 grew to a ~10-fold lower yield
in comparison with the Smith strain and that HaNa1Figure 1 Growth kinetics of MCMV HaNa1 and MCMV Smith in MWFc
curves of HaNa1 and Smith were plotted. The inactivation curve shows the
events. The mean virus titer (log10 TCID50/mL) and standard deviation (n =isolate was more cell-associated than the Smith strain.
Therefore, it can be stated that the Smith strain repli-
cated in MWFc much more easily than the HaNa1
isolate.
Virus titers in tissues
Low dose
After oronasal inoculation of 104 TCID50 per mouse,
MCMV HaNa1 was detected in the nasal mucosa from
14 till 35 dpi with the highest mean virus titer of 103.53
TCID50/g at 14 dpi, in submandibular glands from 14 till
35 dpi with the highest mean virus titer of 104.93
TCID50/g at 21 dpi (Figure 2), and in lungs, plasma, and
saliva only at one time point (14 (n = 1), 21 (n = 2) and
28 (n = 1) dpi, respectively). The other organs (olfactory
bulb, brain, pharynx, trachea, esophagus, small intes-
tines, liver, kidneys, uterus, ovaries, thymus and spleen)
remained all negative (under the detection limit).
MCMV Smith was detected in the nasal mucosa from
14 till 35 dpi and in submandibular glands from 14 till
42 dpi with the highest mean virus titer in the nasal mu-
cosa (103.01 TCID50/g) at 14 dpi and in the submandibu-
lar glands (103.72 TCID50/g) at 17 dpi (Figure 2). Lungs
were positive only at 17 dpi (n = 2). Saliva and plasma
were negative during the course of infection. MCMV
Smith led to a productive infection with virus replication
in the spleen at 17 dpi (n = 3) and 35 dpi (n = 1), in the
liver at 14 dpi (n = 2) and 17 dpi (n = 3), and in the kid-
neys at 14 dpi (n = 1) and 17 dpi (n = 3) (Figure 2). The
other organs (olfactory bulb, brain, pharynx, trachea,
esophagus, small intestines, uterus, ovaries and thymus)
remained all negative (under the detection limit).
High dose
After oronasal inoculation of 106 TCID50 per mouse,
MCMV HaNa1 was detected in the nasal mucosa from 1
dpi till the end of the experiment (49 dpi) with the. The virus titers generated in MWFc were determined, and growth
drop of virus titers at 37 °C in culture medium due to inactivation
3) were shown in the diagram.
Figure 2 Virus titers in the nasal mucosa, lungs, submandibular glands, saliva, plasma, spleen, liver and kidneys. These tissues were
collected from mice upon oronasal inoculation with either a low (104TCID50/mouse, left column) or a high (10
6TCID50/mouse, right column)
inoculation dose. Virus titers (log10 TCID50/g or log10 TCID50/mL) were measured by titration. Open circles represent HaNa1-infected mice and
closed circles represent Smith-infected mice. The detection limit for the titration (102.1 TCID50/g) is shown by the horizontal dotted line.
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submandibular glands from 7 dpi till the end of the ex-
periment 49 dpi with the highest mean virus titer of
106.3 TCID50/g at 14 dpi, and in lungs at 5, 7 and 14 dpi
with a low level of virus replication (Figure 2). At none
of the collected time points post inoculation, infectious
virus was detected in saliva and plasma. The other or-
gans (olfactory bulb, brain, pharynx, trachea, esophagus,
small intestines, liver, kidneys, uterus, ovaries, thymus
and spleen) remained negative throughout the experi-
ment (under the detection limit).
MCMV Smith was detected in the nasal mucosa from
1 dpi till the end of the experiment (49 dpi) with the
highest mean virus titer of 103.63 TCID50/g at 14 dpi, in
submandibular glands from 7 dpi till 35 dpi with the
highest mean virus titer of 103.91 TCID50/g at 14 dpi,
and in lungs from 5 dpi till 14 dpi except 10 dpi with a
low level of virus replication close to the virus detection
limit except at 7 dpi with a virus titer of 104.8 TCID50/g
in 2 out of 3 mice (Figure 2). MCMV Smith led to a pro-
ductive infection with virus replication in the spleen at 7
dpi (n = 2) and 14 dpi (n = 2), in the liver at 7 dpi (n = 2)
and 14 dpi (n = 1), and in the kidneys at 10 dpi (n = 2),
14 dpi (n = 2) and 17 dpi (n = 1) (Figure 2). Infectious
virus was not detected in saliva and plasma at any indi-
cated time point. No virus was detected in the control
mice. The other organs (olfactory bulb, brain, pharynx,
trachea, esophagus, small intestines, uterus, ovaries and
thymus) remained negative throughout the experiment
(under the detection limit).Co-culture of PBMC with MWFc
At none of the collected time points post inoculation,
cell-associated virus was detected by co-culture for both
strains at a low inoculation dose. At a high inoculation
dose, cell-associated virus was detected in PBMC for
both strains: at 7 dpi (n = 2) and 10 dpi (n = 1) in
HaNa1-infected mice; at 7 dpi (n = 2) in Smith-infected
mice.Figure 3 Quantification of MCMV-infected cells in the nasal mucosa, s
individual animals. Forty consecutive cryosections per tissue were evaluated
per 10 mm2 is shown. The average values of infected cells at different timeQuantification of MCMV-infected cells in the nasal
mucosa, lungs and submandibular glands
The nasal mucosa, lungs and submandibular glands
from mice that received a high inoculation dose were
collected at 3, 7, 14 and 35 dpi and the number of
MCMV-infected cells in these organs was quantified.
The same samples from mock-inoculated mice were
negative for MCMV. Figure 3 shows the number of
MCMV-infected cells in these organs.
For HaNa1-infected mice, infected cells in the nasal
mucosa were first detected at 3 dpi (0.09 cells per
10 mm2), peaked at 7 dpi (0.51 cells per 10 mm2) and
dropped sharply afterwards (at 35 dpi: 0.09 cells per
10 mm2). In lungs, they were first detected and also
peaked at 7 dpi (0.47 cells per 10 mm2), decreased after-
wards significantly and were undetectable at 35 dpi. In
submandibular glands, they were first noticed at 7 dpi
(0.13 cells per 10 mm2), peaked at 14 dpi (1.59 cells per
10 mm2), and dropped sharply afterwards (0.80 cells per
10 mm2 at 35 dpi).
For Smith-infected mice, MCMV-infected cells in the
nasal mucosa were first detected at 3 dpi (0.07 cells per
10 mm2), peaked at 7 dpi (0.23 cells per 10 mm2) and
then decreased till 35 dpi (0.08 cells per 10 mm2). In
lungs, they were first detected and also peaked at 7 dpi
(0.72 cells per 10 mm2), afterwards fell dramatically and
were undetectable at 35 dpi. In submandibular glands,
they were first detected at 7 dpi (0.08 cells per 10 mm2),
reached a peak at 14 dpi (0.49 cells per 10 mm2) and de-
creased afterwards (0.05 cells per 10 mm2 at 35 dpi).
Identification of MCMV-infected cells in the nasal mucosa,
lungs and submandibular glands
Identification of the MCMV-infected cells in target tis-
sues would help us to understand the cell tropism of
MCMV. The nasal mucosa, lungs and submandibular
glands from mice inoculated with a high dose were col-
lected at 3, 7, 14 and 35 dpi to be stained for MCMV an-
tigens and cellular markers simultaneously. The
morphology of MCMV-positive cells consisted of a bigubmandibular glands and lungs. Each time point has three
by immunofluorescence microscopy. The number of infected cells
points were connected by lines.
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rim of positive cytoplasm (Figure 4). Since both strains
gave similar results, only staining of cryosections from
HaNa1-infected mice were presented here. In the nasal
mucosa, the infected cells were only found in the olfac-
tory epithelium and nasopharynx associated lymph tis-
sue (NALT) from 3 dpi onwards. Based on our results,
viral proteins were expressed in both sustentacular cells
and neurons in the olfactory epithelium, and in CD68/
CD11c positive cells (macrophages/dendritic cells) but
not in B220/CD3 positive cells (B cells/T cells) in the
NALT. In lungs, epithelial cells and macrophages were
susceptible cell types at 7 and 14 dpi. In submandibular
glands, only epithelial cells were susceptible at 7, 14 and
35 dpi.Serology
Viral-specific antibodies by IPMA
Low dose-MCMV HaNa1-specific antibodies were first
detected at 10 dpi. Afterwards, titers rose and reached a
maximal level at 21 dpi; MCMV Smith-specific anti-
bodies showed a similar course with the exception that
they appeared later (at 14 dpi) (Figure 5). High dose-The
high dose (106 TCID50/mouse) reduced the time of ap-
pearance of antibodies (HaNa1 at 7 dpi; Smith at 10
dpi). Both reached a maximal level at 17 dpi.Subclasses determination by IPMA
Low dose-The results of specific Ig classes and IgG sub-
classes determination showed that only IgG2a was de-
tectable throughout the whole experiment, whereas the
other (IgA, IgM and other IgG subclasses (IgG1, IgG2b,
IgG2c and IgG3)) were not (Table 1). IgG2a subclass
was detected earlier in HaNa1-infected mice at 14 dpi
than in Smith-infected mice at 17 dpi. High dose-IgG2a
was the main antibody subclass (Table 2). IgG1 and
IgG2c antibodies were also detected for both strains
but with lower titers (lower than or equal to 64) albeit
at 35 and 49 dpi.Complement-dependent neutralizing antibodies by NA test
Neutralizing antibodies without adding guinea pig
complement were only detected at 35–49 dpi with
low NA titers (lower than or equal to 2) for both
strains (data not shown). Complement-dependent
neutralizing antibodies from mice inoculated with a
low inoculation dose were first detected at 14 dpi,
afterwards increased till the end of experiment at 49
dpi (Figure 5). A similar pattern was found with a
high inoculation dose, except that neutralizing anti-
bodies appeared earlier at 10 dpi.Discussion
To date, MCMV has been widely used in laboratory
models for studying HCMV infections. Almost all the
laboratory research on MCMV used either the Smith
or the Smith-derived K181 strains, which are the two
standard laboratory MCMV stains [17]. These strains
have been serially passaged in vitro or in vivo for
more than 60 years, which likely caused genetic and
biological changes. Furthermore, non-natural inocula-
tion routes (subcutaneously, intraperitoneally, or
intravenously) have been utilized to inoculate animals
in the previous studies, thus bypassing the mucosal
sites of virus replication and the local immune re-
sponse [4,13]. Therefore, there is limited information
on natural infections with low passaged MCMV.
Here, an MCMV infection model has been established
that mimics natural infection using a recently Belgian
MCMV isolate HaNa1. We found that upon oronasal
inoculation: 1) the nasal mucosa and submandibular
glands were the main sites of productive MCMV repli-
cation; 2) the Smith strain established a productive in-
fection in spleen, liver and kidneys, whereas the
HaNa1 isolate did not; 3) increasing the inoculation
dose strongly elevated virus production in the nasal
mucosa and submandibular glands, and also reduced
the time of appearance of antibodies.
In the present study, it was examined whether HaNa1
and Smith differed in viral growth in vitro and in vivo.
The growth kinetics in vitro demonstrated that the
Smith strain replicated to a ~10-fold higher yield than
the HaNa1 isolate. In contrast to the in vitro situation,
in the nasal mucosa and submandibular glands, HaNa1
replicated to higher titers than Smith in vivo. This is
consistent with their passage history. The MCMV with
more passages in cells grows better in vitro but loses
part of its replication ability at the entry and exit sites
in vivo [32,33].
In vivo, both stains (Smith and HaNa1) were first de-
tected in the nasal mucosa. Increasing the inoculation
dose elevated virus production leading to early detection
and higher virus titers. HaNa1 reached higher virus ti-
ters than Smith. In our study, the nasal mucosa was
shown for the first time to be a susceptible organ for
MCMV. Based on similar characteristics of human and
murine CMVs, we hypothesize that the nasal mucosa
might also be a target organ for HCMV. In line with
this, there have been several reports on the detection of
HCMV in nasopharyngeal carcinomas, sinusitis and
nasal polyposis [34-37]. In lungs, both strains showed a
very restricted replication during the first three weeks
after post inoculation, after which the infection was con-
trolled. Our finding is consistent with a previous study
[38]. The submandibular gland is another target organ
for both strains. In contrast with the viral replication in
Figure 4 Identification of MCMV-infected cells in the nasal mucosa, lungs and submandibular glands. Nuclei were counterstained with
Hoechst (Blue). Co-localization appears yellow in the merged images. The zoomed images show the boxed region of merged layers. Cryosections
of the nasal mucosa were double-stained with antibodies against MCMV antigens (by pα-MCMV Abs) and cell markers: OMP (olfactory neuron
marker), cytokeratin-18 (epithelial marker), CD68 (tissue macrophages) and CD11c (dendritic cells). Olfactory neurons and sustentacular cells of
the olfactory epithelium (olfactory EP) in the nasal mucosa were susceptible for MCMV. Infected cells of NALT in the nasal mucosa were CD68
+/CD11c+. Epithelial cells (cytokeratin-18+) of submandibular glands were susceptible for MCMV. Epithelial cells (cytokeratin-18+) and macrophages
(F4/80+) were positive for MCMV in lungs.
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dibular glands always started after one week post inocu-
lation and lasted longer than 49 dpi post inoculation.
HaNa1 reached much higher virus titers (>100 fold) than
Smith. Similarly to the nasal mucosa, increasing the in-
oculation dose enhanced virus production in the sub-
mandibular glands. CMVs have been reported to mainly
use salivary glands as target organ for virus persistence
and shedding into saliva [13,39,40]. However, in our
study, HaNa1 was detected in saliva only at one time
point within one mouse. The low level of virus titers in
saliva was quite surprising, as CMVs are thought to be
transmitted orally via saliva. In future studies, these con-
flicting data will be further examined.
Cell-associated virus in PBMC was detected at 7–10
dpi for both strains with a high inoculation dose. This
shows that circulating PBMC are involved in the dissem-
ination of MCMV, which corresponds with a previous
study [41]. In our study, only the Smith strain was de-
tectable by virus titration in spleen, liver and kidneys
from the second week post inoculation onwards, provid-
ing evidence that only the Smith strain can establish a
productive infection in internal organs of adult mice,
whereas HaNa1 cannot. The latter is similar to the out-
come of an HCMV primary infection in immunocompe-
tent adults, during which it is only causing a limited
virus-associated spread to the salivary glands but not to
multiple internal organs [42].
Quantification of MCMV-infected cells in the nasal
mucosa, lungs and submandibular glands revealed aFigure 5 Viral-specific antibody titers by IPMA and neutralizing antib
infected mice that had been inoculated with either a low (104TCID50/mous
represents the mean of 3 BALB/c mice ± standard deviation. The detectiongood correlation between virus titers and infected cells.
Identification of MCMV-infected cells demonstrated
that in the nasal mucosa, olfactory neurons as well as
sustentacular cells in the olfactory neuroepithelium and
CD68/CD11c positive cells (macrophages/dendritic cells)
in NALT were the main susceptible cell types. Targeting
the olfactory neurons raised the question if CMV may
damage the smell [43,44]. This will be investigated in the
future. According to the staining results, CD68/CD11c
positive cells (macrophages/dendritic cells) in NALT
were infected from 3 dpi onwards, which indicates that
NALT plays a very important role in MCMV infection.
Therefore, we presume that the virus may be transmit-
ted via lymphatic circulation to draining lymph nodes,
ending up in the blood circulation. In lungs, both epithe-
lial cells and macrophages are susceptible to both
MCMV strains, which are the main cause of pneumon-
itis caused by MCMV [21,38]. It is also a frequently ob-
served manifestation of HCMV infection [45,46]. In
submandibular glands, epithelial cells are the main sus-
ceptible cell type for both MCMV strains, which is con-
sistent with earlier published data [47]. However, up till
now it is unclear how CMV reaches the submandibular
glands and becomes transferred to the epithelial cells.
Serological analysis showed that IgG2a was the anti-
body subclass that was mainly produced except that low
titers of IgG1 and IgG2c were also detected in mice in-
oculated with a high dose at 35–49 dpi. IgM was not de-
tected through the whole course of the experiments for
both MCMV strains. This could be due to the lowody (NA) titers by NA. They were determined in the Smith or HaNa1-
e) or a high (106TCID50/mouse) inoculation dose. Each time point
limit was shown by the dotted line.
Table 1 Course of isotype-specific anti-MCMV HaNa1 or anti-MCMV Smith antibody titers in BALB/c mice inoculated with
104TCID50 per mouse
Strains Classes/
subclasses
Antibody titers
1d 3d 5d 7d 10d 14d 17d 21d 28d 35d 42d 49d
MCMV HaNa1 IgA −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgM −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG1 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG2a −/−/- −/−/- −/−/- −/−/- −/−/- 32/−/− 32/32/16 64/32/64 128/256/128 128/64/128 128/128/128 128/128/128
IgG2b −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG2c −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG3 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
MCMV Smith IgA −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgM −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG1 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG2a −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- 32/32/32 32/64/64 64/128/32 128/64/128 128/64/128 128/128/128
IgG2b −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG2c −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
IgG3 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/- −/−/-
“-” represents that the antibody titer was under the detection limit (1/16).
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sistent with our positive control (low sensitivity of the
mice adapted influenza-specific IPMA), or the suppres-
sive effect of MCMV on the production of IgM by T cell
cytokines. T cell cytokines are responsible for the im-
munoglobulin class switching mechanism in mouse and
human [48]. The strong induction of IgG2a is generally
known to be mediated by interferon γ (IFNγ) [49,50].Table 2 Course of isotype-specific anti-MCMV HaNa1 or anti-M
106TCID50 per mouse
Strains Classes/
subclasses
Antibody titers
1d 3d 5d 7d 10d 14d
MCMV HaNa1 IgA −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgM −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG1 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG2a −/−/- −/−/- −/−/- −/−/- 64/16/32 256/
IgG2b −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG2c −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG3 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
MCMV Smith IgA −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgM −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG1 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG2a −/−/- −/−/- −/−/- −/−/- 32/-/64 64/1
IgG2b −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG2c −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
IgG3 −/−/- −/−/- −/−/- −/−/- −/−/- −/−/
“-” represents that the antibody titer was under the detection limit (1/16).Because IFNγ as well as other T cell cytokines were not
evaluated in this study, we could not assess the role of
IFNγ in the orientation of the antibody isotype switch.
The complement-dependent neutralization test demon-
strated that complement plays a critical role in neutraliz-
ing MCMV since antibodies without complement/with
inactivated complement did not neutralize MCMV in-
fection. Since IgG2a is the predominant viral-specificCMV Smith antibody titers in BALB/c mice inoculated with
17d 21d 35d 49d
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- 128/16/64 32/64/64
128/256 256/256/512 128/256/256 1024/1024/1024 256/1024/1024
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- −/−/- 64/32/64
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- -/32/- 64/32/-
28/128 256/128/256 512/512/256 512/512/1024 1024/512/512
- −/−/- −/−/- −/−/- −/−/-
- −/−/- −/−/- 16/32/16 64/16/64
- −/−/- −/−/- −/−/- −/−/-
Zhang et al. Veterinary Research  (2015) 46:94 Page 12 of 13antibody, we can state that complement-dependent
IgG2a-mediated inactivation of MCMV is an important
anti-MCMV defense. This is consistent with the charac-
teristics of antibody isotype IgG2a to fix complement in
mice [51]. Neutralizing antibody titers were higher at 35
and 49 dpi, which may explain in part the clearance of
HaNa1 at 49 dpi and Smith at 35 and 49 dpi in subman-
dibular glands in the high inoculation dose group. Simi-
lar patterns also occurred for both strains at 42 and 49
dpi in the low inoculation dose groups. The control of
virus infection at the end of the experiments is also most
probably mediated by the cell-mediated immunity,
which is generally considered to be the most important
factor in controlling CMV infections [52,53].
In summary, mouse models with MCMV that are
mimicking natural infection were set up in the present
study. By the use of two MCMV strains (Smith and
HaNa1), we found that infections started in the upper
respiratory tract, after which the virus spreads via a cell-
associated viremia to other target organs such as spleen,
liver, kidneys and submandibular glands. The Smith
strain caused a productive infection in spleen, liver and
kidneys, whereas the HaNa1 isolate did not. The latter is
similar to the outcome of an HCMV primary infection
in immunocompetent hosts; it is only causing a limited
virus-associated spread to the salivary glands but not to
multiple internal organs. Therefore, the newly isolated
MCMV HaNa1 isolate is interesting to be used in mouse
models in order to get better insights into HCMV nat-
ural infections in immunocompetent hosts via oronasal
exposure. Increasing the inoculation dose strongly ele-
vated virus production in the nasal mucosa and subman-
dibular glands and cell-associated viremia during the
early stage of infection, reduced the time of appearance
of antibodies, and increased the level of antibodies. In
this study, we predominantly focused on the kinetics of
virus production in different organs. As known for a
long time, CMVs spread in a strong cell-associated way.
This was not investigated in depth in the present study.
Therefore, in the near future, we will focus on the kinet-
ics of MCMV infected leukocytes (cell-associated virus)
in order to better understand the viral link between the
respiratory tract, as portal of entry, and the submandibu-
lar glands, as portal of exit. It is very important to
understand how MCMV starts up replication in the sub-
mandibular glands and maintains its replication in this
organ for a long period of time.
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